HVTN 702 is but one of many vaccine trials underway, researchers note.
Health care providers and educators need to acknowledge the impact of clinical bias and reframe sexual health education when it comes to tending to cisgender women's needs, Chase Alston writes.
Many fear the push to put more people on the new brand-name drug before Truvada goes generic this year.
This may be a temporary setback, but long-acting antiretroviral therapy is still on the way, experts say.
Pre-exposure prophylaxis (PrEP) is a vital part of ending HIV, but ads targeting people to join lawsuits are planting needless fears in patients, three leading HIV specialists write.
What Needs to Happen Before California Pharmacies Can Sell PrEP and PEP Without an Initial Prescription
Pharmacists will increasingly play a role in pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) access in California.
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
This inspiring moment from the U.S. Conference on AIDS illustrates how relationships can produce results for advocates.
The ECHO trial faces backlash and criticism.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.